These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34921734)

  • 1. Microenvironment and drug resistance in acute myeloid leukemia: Do we know enough?
    Ganesan S; Mathews V; Vyas N
    Int J Cancer; 2022 May; 150(9):1401-1411. PubMed ID: 34921734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia.
    Fabiani E; Cicconi L; Nardozza AM; Cristiano A; Rossi M; Ottone T; Falconi G; Divona M; Testi AM; Annibali O; Castelli R; Lazarevic V; Rego E; Montesinos P; Esteve J; Venditti A; Della Porta M; Arcese W; Lo-Coco F; Voso MT
    Cancer Med; 2021 Jun; 10(12):3839-3847. PubMed ID: 34042280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia.
    Wang A; Zhong H
    Hematology; 2018 Dec; 23(10):729-739. PubMed ID: 29902132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
    Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
    Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radar plots facilitate differential diagnosis of acute promyelocytic leukemia and NPM1+ acute myeloid leukemia by flow cytometry.
    Gupta M; Jafari K; Rajab A; Wei C; Mazur J; Tierens A; Hyjek E; Musani R; Porwit A
    Cytometry B Clin Cytom; 2021 Jul; 100(4):409-420. PubMed ID: 33301193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Microenvironment in Resistance to Therapy in AML.
    Tabe Y; Konopleva M
    Curr Hematol Malig Rep; 2015 Jun; 10(2):96-103. PubMed ID: 25921386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy-related acute myeloid leukemia (t-AML) with poor-risk cytogenetics in two patients with persistent molecular complete remission of acute promyelocytic leukemia.
    Ojeda-Uribe M; Schneider A; Luquet I; Berceanu A; Cornillet-Lefebvre P; Jeandidier E; Lioure B; Ades L; Mauvieux L; Himberlin C
    Eur J Haematol; 2012 Sep; 89(3):267-72. PubMed ID: 22591288
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Nguyen CH; Grandits AM; Purton LE; Sill H; Wieser R
    Cell Cycle; 2020 Oct; 19(20):2573-2588. PubMed ID: 32900260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current clinical trials using new targeted therapies for myeloid leukemia and the research trends].
    Ishizawa J; Saya H
    Nihon Rinsho; 2009 Oct; 67(10):1932-7. PubMed ID: 19860193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transformation from acute promyelocytic leukemia to acute myeloid leukemia with a CEBPA double mutation: A case report and review of the literature.
    Sun Y; Wang C; Sun Y; Wang J; Rong C; Wu A; Ouyang G; Sheng L
    Medicine (Baltimore); 2021 Feb; 100(5):e24385. PubMed ID: 33592885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of interleukins in acute myeloid leukemia.
    Wang Y; Tang X; Zhu Y; Yang XX; Liu B
    Leuk Lymphoma; 2023; 64(8):1400-1413. PubMed ID: 37259867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.
    Hou HA; Lin YC; Kuo YY; Chou WC; Lin CC; Liu CY; Chen CY; Lin LI; Tseng MH; Huang CF; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
    Ann Hematol; 2015 Feb; 94(2):211-21. PubMed ID: 25241285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Strategies to improve therapeutic efficacy in childhood acute myeloid leukemia].
    Zhu XF
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 Feb; 16(2):108-10. PubMed ID: 24568899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.
    Strickland SA; Shaver AC; Byrne M; Daber RD; Ferrell PB; Head DR; Mohan SR; Mosse CA; Moyo TK; Stricker TP; Vnencak-Jones C; Savona MR; Seegmiller AC
    Leuk Res; 2018 Feb; 65():67-73. PubMed ID: 29310020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis.
    Diab A; Zickl L; Abdel-Wahab O; Jhanwar S; Gulam MA; Panageas KS; Patel JP; Jurcic J; Maslak P; Paietta E; Mangan JK; Carroll M; Fernandez HF; Teruya-Feldstein J; Luger SM; Douer D; Litzow MR; Lazarus HM; Rowe JM; Levine RL; Tallman MS
    Leuk Res; 2013 Jan; 37(1):32-6. PubMed ID: 23102703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel MLL/KMT2A-MON2 fusion in a child with therapy-related acute myeloid leukemia after treatment for acute promyelocytic leukemia.
    Gong Y; Wang M; Shen H; Chen Y; Cen J; Yin X; Yao L
    Mol Carcinog; 2021 Nov; 60(11):721-725. PubMed ID: 34236108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.
    Leith CP; Kopecky KJ; Godwin J; McConnell T; Slovak ML; Chen IM; Head DR; Appelbaum FR; Willman CL
    Blood; 1997 May; 89(9):3323-9. PubMed ID: 9129038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal Acute Myeloid Leukemia and Acute Promyelocytic Leukemia.
    Abramowitz J; Neuman T; Perlman R; Ben-Yehuda D
    BMC Med Genomics; 2017 Mar; 10(1):18. PubMed ID: 28340577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia.
    Long L; Assaraf YG; Lei ZN; Peng H; Yang L; Chen ZS; Ren S
    Drug Resist Updat; 2020 Sep; 52():100703. PubMed ID: 32599434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia.
    Xia B; Tian C; Guo S; Zhang L; Zhao D; Qu F; Zhao W; Wang Y; Wu X; Da W; Wei S; Zhang Y
    Leuk Res; 2015 Jan; 39(1):92-9. PubMed ID: 25443862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.